Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

So far, Altmetric has seen 32 X posts from 23 X users, with an upper bound of 102,537 followers.

RT @LabNaing: On #RareDiseaseDay2021 , Single-agent pembrolizumab has modest efficacy as a salvage therapy in ACC https://t.co/NfW1rWcjuf b…

RT @LabNaing: On #RareDiseaseDay2021 , Single-agent pembrolizumab has modest efficacy as a salvage therapy in ACC https://t.co/NfW1rWcjuf b…

RT @LabNaing: On #RareDiseaseDay2021 , Single-agent pembrolizumab has modest efficacy as a salvage therapy in ACC https://t.co/NfW1rWcjuf b…

On #RareDiseaseDay2021 , Single-agent pembrolizumab has modest efficacy as a salvage therapy in ACC https://t.co/NfW1rWcjuf by Mouhammed Amir Habra, @recnac1 @SWOG @DrNancyPerrier @Abdul_Zarifa @ANaingMD and colleagues published @jitcancer @rarediseaseda

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 28 additional X posts.